Femasys (NASDAQ:FEMY) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Femasys (NASDAQ:FEMY) issued its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.07, FiscalAI reports. The firm had revenue of $0.81 million during the quarter, compared to the consensus estimate of $1.06 million. Femasys had a negative net margin of 960.80% and a negative return on equity of 764.26%.

Femasys Trading Up 11.8%

Shares of FEMY traded up $0.04 during trading hours on Tuesday, reaching $0.42. 1,212,277 shares of the company traded hands, compared to its average volume of 648,063. Femasys has a 12 month low of $0.31 and a 12 month high of $1.34. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $0.63. The company has a market capitalization of $25.38 million, a price-to-earnings ratio of -0.58 and a beta of -2.53.

Institutional Trading of Femasys

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp lifted its holdings in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the period. Kovack Advisors Inc. purchased a new position in shares of Femasys during the 4th quarter worth approximately $27,000. Osaic Holdings Inc. bought a new position in shares of Femasys in the 2nd quarter worth approximately $45,000. HRT Financial LP bought a new position in shares of Femasys in the 4th quarter worth approximately $30,000. Finally, Cetera Investment Advisers purchased a new position in shares of Femasys in the 4th quarter valued at approximately $36,000. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Lake Street Capital assumed coverage on Femasys in a report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price target on the stock. Wall Street Zen lowered Femasys from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.